International News In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA Office of International Programs: OIP action plan will coordinate agency's international activities with "overall U.S. government objectives," Commissioner Mark McClellan says in Feb. 27 memo to agency employees. Charged with leading FDA efforts on embassy relations and trade agreements, the office will "leverage resources with counterpart agencies on a risk-benefit basis." Standard operating procedures will be developed in the coming weeks...
You may also be interested in...
Global Device Market Barriers, Strategies Detailed For U.S. Trade Report
Increased medical equipment import tariffs of up to 51% within India's 2002-2003 budget will add millions of dollars in costs for U.S. device companies, AdvaMed asserts in a Dec. 13 statement to the Office of the U.S. Trade Representative
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.